Entera Bio Stock Performance
| ENTX Stock | USD 2.05 0.01 0.49% |
Entera Bio has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.62, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Entera Bio will likely underperform. Entera Bio right now shows a risk of 4.07%. Please confirm Entera Bio potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Entera Bio will be following its price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Entera Bio are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Entera Bio may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Actual Historical Performance (%)
One Day Return 0.49 | Five Day Return 3.02 | Year To Date Return (8.89) | Ten Year Return (67.36) | All Time Return (67.36) |
1 | Acquisition by Galitzer Hillel of 26316 shares of Entera Bio subject to Rule 16b-3 | 04/28/2025 |
2 | Insider Trading | 05/08/2025 |
3 | Disposition of 150000 shares by Gregory Burshtein of Entera Bio at 1.99 subject to Rule 16b-3 | 05/12/2025 |
4 | Entera Bio Registers 100 Million Mixed Securities Shelf Offering ENTX Stock News | 05/30/2025 |
5 | OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1Glucagon Tablet Candidate for ... | 06/25/2025 |
6 | Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual... | 06/26/2025 |
7 | OPKO Health to Present OPK-88006 Data at ENDO 2025 - MSN | 07/03/2025 |
8 | OPKO Health and Entera Bio Announce Abstract on PKPD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress | 07/08/2025 |
9 | Acquisition by Yaacov-garbeli Dana of 26316 shares of Entera Bio subject to Rule 16b-3 | 07/16/2025 |
| Begin Period Cash Flow | 11.1 M | |
| Total Cashflows From Investing Activities | -3000.00 |
Entera Bio Relative Risk vs. Return Landscape
If you would invest 196.00 in Entera Bio on April 22, 2025 and sell it today you would earn a total of 9.00 from holding Entera Bio or generate 4.59% return on investment over 90 days. Entera Bio is currently generating 0.1533% in daily expected returns and assumes 4.0702% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Entera, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Entera Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entera Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Entera Bio, and traders can use it to determine the average amount a Entera Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0377
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ENTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.07 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.15 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Entera Bio is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Entera Bio by adding it to a well-diversified portfolio.
Entera Bio Fundamentals Growth
Entera Stock prices reflect investors' perceptions of the future prospects and financial health of Entera Bio, and Entera Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entera Stock performance.
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (61.02) % | ||||
| Current Valuation | 80.82 M | ||||
| Shares Outstanding | 45.45 M | ||||
| Price To Earning | 2.10 X | ||||
| Price To Book | 4.81 X | ||||
| Price To Sales | 417.83 X | ||||
| Revenue | 181 K | ||||
| Gross Profit | 9 K | ||||
| EBITDA | (9.54 M) | ||||
| Net Income | (9.54 M) | ||||
| Cash And Equivalents | 17.28 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 272 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.89 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | (6.82 M) | ||||
| Earnings Per Share | (0.26) X | ||||
| Market Capitalization | 93.18 M | ||||
| Total Asset | 9.39 M | ||||
| Retained Earnings | (113.93 M) | ||||
| Working Capital | 7.8 M | ||||
| Current Asset | 8.46 M | ||||
| Current Liabilities | 7.64 M | ||||
About Entera Bio Performance
Evaluating Entera Bio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Entera Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entera Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.2 K | -1.2 K | |
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (1.17) | (1.23) | |
| Return On Assets | (1.02) | (1.07) | |
| Return On Equity | (1.18) | (1.24) |
Things to note about Entera Bio performance evaluation
Checking the ongoing alerts about Entera Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Entera Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Entera Bio had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 181 K. Net Loss for the year was (9.54 M) with profit before overhead, payroll, taxes, and interest of 9 K. | |
| Entera Bio currently holds about 17.28 M in cash with (6.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Entera Bio has a poor financial position based on the latest SEC disclosures | |
| Roughly 24.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Acquisition by Yaacov-garbeli Dana of 26316 shares of Entera Bio subject to Rule 16b-3 |
- Analyzing Entera Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entera Bio's stock is overvalued or undervalued compared to its peers.
- Examining Entera Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Entera Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entera Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Entera Bio's stock. These opinions can provide insight into Entera Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.